A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak jajnika, otrzewnej lub jajowodu z określonym typem histologicznym (wysokiego stopnia surowiczy).
✗ Disqualifies
- •Choroba, która od początku nie reagowała na leczenie platyną.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 6, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (15)
Highlands Oncology Group
Springdale, United States
Yale University
New Haven, United States
Florida Cancer Specialists & Research Institute
Sarasota, United States
Massachusetts General Hospital
Boston, United States
Karmanos Cancer Institute
Detroit, United States
Mayo Clinic
Rochester, United States
NEXT Virginia
Fairfax, United States
Icon Cancer Centre
South Brisbane, Australia
Cancer Research SA
Aberfoyle Park, Australia
Hospital Universitario Dexeus - Grupo Quironsalud
Barcelona, Spain
Clínica Universidad Navarra
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
Clínica Universidad de Navarra
Pamplona, Spain
Hospital Quironsalud Madrid
Pozuelo de Alarcón, Spain
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.